Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara, Sarah M. Paul, Marcin Kowanetz et al. · Nature Medicine · 2018
Cited by 1,157 works. doi:10.1038/s41591-018-0134-3
Authors
- David R. Gandara
- Sarah M. Paul
- Marcin Kowanetz
- Erica Schleifman
- Wei Zou
- Yan Li
- Achim Rittmeyer
- Louis Fehrenbacher
- Geoff A. Otto
- Christine M. Malboeuf
- Daniel S. Lieber
- Doron Lipson
- Jacob Silterra
- Lukas C. Amler
- Todd Riehl
- Craig A. Cummings
- Priti S. Hegde
- Alan Sandler
- Marcus D. Ballinger
- David A. Fabrizio
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Signatures of mutational processes in human cancer
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Cancer Genome Landscapes
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial